



# **Technical seminar on BREXIT Pharmaceuticals related issues**

**Brussels, 8 March 2018**

# UK's withdrawal from the EU

Main ongoing workstrands:

- - Withdrawal agreement ("Article 50 agreement")
- - "Transition period" (part of the "Article 50 agreement")
- - "Future relationship"

Bottom-line: UK will be a "third country" on 30/3/19

# Withdrawal agreement

- - "Winding down" of EU membership
- - Draft text has been published (but not yet discussed with the UK)
- - Only aspects agree so far are (i) citizen's right; (ii) financial settlement and (iii) principles re. IE


# "Transition period" (i)

- - Full acquis applies to the UK
- - Dynamic reference, i.e. including acquis that starts applying in the transition period
- - No UK participation in EU institutions or EU bodies
- - No UK participation in Member State meetings (subject to exceptions)
- - No UK role as "leading authority"
- - Full role of Court of Justice, Commission, Court of Auditors, etc.
- - UK remains subject to obligations (but not rights) of international agreements concluded by the EU
- - Financial settlement = rights and obligations of the MFF

# "Transition period" (ii)

- *Duration: until 31 December 2020 (incl.)*
- *Agreement still needs to be negotiated, agreed, and ratified*
- *!! Do not rely on the "transition period" !!*

# Future economic relationship



# Brexit – Next steps

